Potential impact of the bivalent rLP2086 vaccine onNeisseria meningitidiscarriage and invasive serogroup B disease

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

Laboratory-Based Surveillance of Neisseria meningitidis Isolates from Disease Cases in Latin American and Caribbean Countries, SIREVA II 2006–2010

(2012) Ana Belén Ibarz-Pavón et al.   PLoS One

Carriage ofNeisseria meningitidisin Europe: a review of studies undertaken in the region

(2011) Montse Soriano-Gabarró et al.   Expert Review of Anti-Infective Therapy

New frontiers in meningococcal vaccines

(2011) Annaliesa S Anderson et al.   Expert Review of Vaccines

Young-adult carriers ofNeisseria meningitidisin Puglia (Italy): Will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?

(2011) Cinzia Germinario et al.   Human vaccines & immunotherapeutics

Genotypic and Phenotypic Characterization of Carriage and Invasive Disease Isolates of Neisseria meningitidis in Finland

(2011) U. Jounio et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates

(2011) Jane W. Marsh et al.   VACCINE

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Persistence, Replacement, and Rapid Clonal Expansion of Meningococcal Carriage Isolates in a 2008 University Student Cohort

(2010) F. A. Bidmos et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

(2010) Dlawer A.A. Ala’Aldeen et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide

(2009) Lisa K. McNeil et al.   VACCINE

Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis

(2009) David S. Stephens   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE